Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis

Takashi Sakakibara, Hideki Ishii, Takanobu Toriyama, Toru Aoyama, Hiroshi Takahashi, Daisuke Kamoi, Yoshihiro Kawamura, Kazuhiro Kawashima, Kohei Yoneda, Tetsuya Amano, Miho Tanaka, Daiji Yoshikawa, Mutsuharu Hayashi, Tatsuaki Matsubara, Toyoaki Murohara

研究成果: ジャーナルへの寄稿学術論文査読

36 被引用数 (Scopus)


Background: Even in the drug-eluting stent era, adverse cardiac events, including restenosis after percutaneous coronary intervention (PCI), have been more frequently seen in patients on hemodialysis (HD) than in non-HD patients. The objective of this study was to compare the sirolimus-eluting stent (SES) and everolimus-eluting stent (EES) for prevention of adverse cardiac events, including restenosis, in HD patients. Methods and Results: A total of 100 consecutive patients on HD who underwent PCI were enrolled and randomly assigned to receive SES or EES. Although there was no difference between the 2 groups in baseline patient and lesion characteristics, the angiographic restenosis rate at 8-month follow-up was 21.2% in the SES group and 8.7% in the EES group (P=0.041). Significant differences were also seen in % diameter stenosis (%DS), minimal lumen diameter, and late lumen loss at 8-month follow-up (P=0.0024, P=0.0040, and P=0.033, respectively). During the 1-year follow-up, major adverse cardiac events occurred in 11 (22.0%) patients in the SES group and in 5 (10.0%) patients in the EES group (P=0.10). Conclusions: The use of EES was as safe as that of SES. Moreover, EES significantly prevented restenosis in patients on maintenance HD compared with SES.

ジャーナルCirculation Journal
出版ステータス出版済み - 2012

All Science Journal Classification (ASJC) codes

  • 循環器および心血管医学


「Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。